IMMU Immunomedics Inc.

13.12
-0.14  -1%
Previous Close 13.26
Open 13.35
Price To Book 7.25
Market Cap 2498411988
Shares 190,427,743
Volume 5,792,731
Short Ratio
Av. Daily Volume 3,490,148

SEC filingsSee all SEC filings

  1. 8-K - Current report 19532081
  2. 8-K - Current report 19529616
  3. 8-K - Current report 181256083
  4. 8-K - Current report 181251401
  5. 8-K - Current report 181238683

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated.
SACITUZUMAB GOVITECAN
Castration-resistant prostate cancer (CRPC)
Phase 2 pivotal trial to be initiated early June 2018.
SACITUZUMAB GOVITECAN - TROPHY U-01
Urothelial cancer
CRL issued January 17, 2019.
SACTUZUMAB GOVITECAN (IMMU-132)
Cancer - metastatic triple-negative breast cancer
Phase 2 update provided at ASCO June 2016. Ongoing through 2017.
SACITUZUMAB GOVITECAN
Non-small cell lung cancer (NSCLC)
Phase 2 interim data presented April 2016
Labetuzumab govitecan
Metastatic colorectal cancer (mCRC)
Phase 3 trial terminated due to poor efficacy
Clivatuzumab tetraxetan
Cancer - Pancreatic
Endpoints not met July 2015
Epratuzumab (EMBODY 1 and 2)
Lupus
Presentation at ASCO June 2018. ORR 31%.
SACTUZUMAB GOVITECAN (IMMU-132)
HR+/HER2- metastatic breast cancer

Latest News

  1. Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Immunomedics, Inc. 
  2. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of XPO, IMMU, AXGN and AGN
  3. CLASS ACTION UPDATE for YOGA, IMMU and YRIV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  4. INVESTOR NOTICE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunomedics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  5. SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Immunomedics, Inc. (IMMU) and Lead Plaintiff Deadline: February 25, 2019
  6. Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs
  7. Today's Research Reports on Trending Tickers: Amarin and Immunomedics
  8. SHAREHOLDER ALERT: YOGA YRCW IMMU YRIV: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
  9. INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunomedics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  10. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immunomedics Inc. - IMMU
  11. Kessler Topaz Meltzer & Check, LLP Reminds Immunomedics, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit
  12. SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunomedics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  13. IMMU LOSSES ALERT: Rosen Law Firm Reminds Immunomedics, Inc. Investors of Important Deadline in Case Seeking to Recover Investor Losses – IMMU
  14. SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Immunomedics, Inc. (IMMU) & Lead Plaintiff Deadline: February 25, 2019
  15. Do Options Traders Know Something About Immunomedics (IMMU) Stock We Don't?
  16. IMMUNOMEDICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Immunomedics, Inc. - IMMU
  17. Why Tesla, Immunomedics, and Nautilus Slumped Today
  18. Why Immunomedics Stock Is Getting Hammered Today
  19. Here's Why Immunomedics Plummeted on Friday

SEC Filings

  1. 8-K - Current report 19532081
  2. 8-K - Current report 19529616
  3. 8-K - Current report 181256083
  4. 8-K - Current report 181251401
  5. 8-K - Current report 181238683
  6. CT ORDER - Confidential treatment order 181221004
  7. 10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405] 181218682
  8. CT ORDER - Confidential treatment order 181191760
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166533
  10. 8-K - Current report 181166320